All In Biotech

NDA 020329 · Pfizer

Glucotrol Xl

Glipizide · Oral · Sulfonylurea

Last checked: Nov 20, 2026Latest source record: Aug 3, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1994

Apr 26, 1994

Approved uses

3

Original approval plus efficacy supplements

Registered trials

40

14 Phase 3, 1 recruiting

FAERS reports

61,002

34,236 serious, 5,360 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 21, 2026.

GLUCOTROL XL is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. GLUCOTROL XL is a sulfonylurea indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus Limitations of Use: Not for treatment of type 1 diabetes or diabetic ketoacidosis 1.1 Limitations of Use GLUCOTROL XL is not recommended for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis.

Mechanism: Glipizide primarily lowers blood glucose by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. Sulfonylureas bind to the sulfonylurea receptor in the pancreatic beta-cell plasma membrane, leading to closure of the ATP-sensitive potassium channel, thereby stimulating the release of insulin.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 1, 2002 Supplement 2 · Efficacy LabelLetter
  • Feb 4, 1998 Supplement 1 · Efficacy
  • Apr 26, 1994 Original approval · Type 3 - New Dosage Form
3 products under this application
  • GLUCOTROL XL · GLIPIZIDE 2.5MG · TABLET, EXTENDED RELEASE, ORAL · Discontinued · TE AB
  • GLUCOTROL XL · GLIPIZIDE 5MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • GLUCOTROL XL · GLIPIZIDE 10MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Glipizide" as an intervention, any sponsor and status, largest first.

All 40 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • blood glucose increased6,720
  • nausea4,584
  • drug ineffective3,585
  • diarrhoea3,419
  • fatigue3,075
  • weight decreased2,839
  • dizziness2,489
  • dyspnoea2,463
  • vomiting2,290
  • blood glucose decreased2,246
  • asthenia2,140
  • pain2,126

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,259
20051,577
20062,728
20072,467
20082,046
20092,050
20102,348
20112,436
20122,470
20132,409
20142,696
20154,666
20164,388
20174,042
20184,166
20194,037
20203,225
20212,613
20222,209
20231,915
20241,925
20251,994
20261,336

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Glucotrol XL (Glipizide)

2024 spending

$52K

Beneficiaries

293

901 claims

Per beneficiary

$177

$0.51 per unit

View as table
YearSpending
2020$845,441
2021$697,018
2022$157,698
2023$91,077
2024$51,977

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 222 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.